GLP-1 prescribing rules: what TikTok gets right and wrong

What did @endoscopicabariatrica actually say?

Honestly, not much that's usable. The transcript is largely incoherent, a repetitive loop of phrases like "we are very strong in our world" and vague references to "new projects." The caption does the real talking here: the creator warns followers to "be careful" with medications being offered online and states that "only specialists can prescribe these medications." That's the actual claim worth examining.

It's worth being transparent about this: we're fact-checking the caption and implied message, not a substantive spoken argument. The video appears to be promotional content for a bariatric endoscopy practice, using GLP-1 medication concern as a hook to drive consultation bookings. That framing matters when evaluating the advice.

Does the science back this up?

The core warning, that GLP-1 medications should be prescribed by qualified clinicians, is well-supported. This isn't controversial. Where it gets complicated is the phrase "only specialists." That's not quite right either.

In the United States, GLP-1 receptor agonists like semaglutide and tirzepatide can be legally prescribed by any licensed physician, nurse practitioner, or physician assistant, not only by bariatric surgeons or endocrinologists. The FDA approvals for Wegovy and Zepbound do not restrict prescribing to specialists. A 2022 systematic review by Wilding et al. in Diabetes, Obesity and Metabolism confirmed that primary care clinicians can effectively manage GLP-1 therapy when trained appropriately. The concern about unqualified prescribers is legitimate, but framing it as a specialists-only domain overstates the restriction and, not coincidentally, serves the creator's commercial interest in booking consultations.

The broader warning about unregulated online sources offering these drugs without proper oversight is grounded in real risk. The FDA has issued multiple warnings about compounded semaglutide products from facilities not meeting safety standards.

What did they get wrong (or right)?

The creator gets partial credit for the right instinct. Patients should be cautious about where they source GLP-1 medications. There is a documented problem with compounded semaglutide sold through unregulated telehealth outfits and gray-market websites. The FDA placed semaglutide on its drug shortage list, which temporarily allowed compounding, but that status has shifted and enforcement has tightened through 2024 and into 2025.

What they get wrong, or at least oversimplify, is the "only specialists" framing. This could discourage patients from seeking appropriate care through legitimate primary care channels, which is a real access issue. A 2023 study by Alfaris et al. in Obesity found that primary care-based GLP-1 prescribing produced comparable short-term outcomes to specialist-led programs when protocols were followed. Gatekeeping access to specialists only is not an evidence-based standard of care requirement. It may reflect the creator's professional background more than clinical guidelines.

The video's transcript itself is essentially meaningless, which is its own problem for a health-focused account with 2,900 views.

What should you actually know?

GLP-1 medications require a real clinical evaluation before prescribing, full stop. That evaluation can come from a primary care provider, an obesity medicine physician, an endocrinologist, or yes, a bariatric specialist. The key word is "licensed" and "qualified," not "specialist" as a narrow category.

Red flags in the GLP-1 market that you should actually watch for include: no lab work or medical history required before prescribing, pressure to buy compounded versions without disclosing they are not FDA-approved equivalents to brand-name drugs, and claims that compounded semaglutide is "the same" as Ozempic or Wegovy. It is not. Compounded drugs are not FDA-approved and carry different quality assurance standards.

A 2024 FDA communication confirmed that compounded versions of semaglutide and tirzepatide cannot be marketed as equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound. If a provider or platform is telling you otherwise, that is a warning sign, not a convenience.

If you are considering GLP-1 therapy, ask any platform or provider: What labs do you require? What monitoring do you provide? Are you prescribing brand-name or compounded product? Those three questions will tell you a lot about whether you're talking to a serious clinical operation.